Protocol Ledger

NCT03535194 · Phase III · COMPLETED

A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)

Interventional Phase III clinical trial protocol NCT03535194 sponsored by Eli Lilly and Company in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-06-26 Enrollment: 1,484 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03535194
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)1,484 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03535194
Protocol FieldVerified Registry Value
NCT IdentifierNCT03535194
Consolidated Lead SponsorEli Lilly and Company
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment1,484 participants (ACTUAL)
Registered Start Date2018-06-26
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03535194
Hospital Research SiteLocationSite Profile
University of Alabama at BirminghamBirmingham, ALOpen Hospital Dossier ->
USC Norris Comprehensive Cancer Center and Keck MedicineLos Angeles, CAOpen Hospital Dossier ->
Clinical Science InstituteSanta Monica, CAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Eli Lilly and Company across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI